Next Steps For NuVasive Following CEO Resignation

The resignation of CEO Alex Lukianov could signal a shift in the spine firm's approach to sales and profitability that could ultimately make NuVasive as a more attractive acquisition candidate.

NuVasive CEO Alex Lukianov has resigned amid reports that he did not follow the company’s expense reimbursement and personnel policies. Board member and former Life Technologies’ CEO Greg Lucier will take over on an interim basis.

Analysts say the move could signal a shift in its approach to sales and profitability and transform NuVasive into a

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Archive

More from Medtech Insight

Beyond The Bladder: Incontinence Impacts Mental Health

 
• By Brian Bossetta

In recognition of Mental Health Awareness month, Sarah Jenkins, executive director at the National Association for Continence, discussed the mental health issues that often come with incontinence.

AI Rollout Aims To Accelerate FDA’s Product Review Process

 
• By Elizabeth Orr

The FDA plans to implement artificial intelligence in its scientific review process by 30 June, following a successful pilot. The agency hopes the tool will reduce nonproductive tasks for reviewers amid recent staff cuts. A Chief AI Officer will oversee the rollout and integration.

Access To Library Tools Being Restored At US FDA

 
• By Sue Sutter and Derrick Gingery

Agency staff once again have access to the Lexis-Nexis legal and news database, but are still waiting for access to journals and laid off librarians have not been reinstated.